 |
160 Products |  |
813 Diseases | | 160 Products |
|
1554 Trials |  |
75234 News |  |
| «12...949596979899100101102103104...858859» |
- Blincyto (blinatumomab) / Astellas, Amgen
SAFETY AND EFFICACY COMPARISON OF HUMANIZED CD19 CAR-T VERSUS BLINATUMOMAB THERAPY FOR RELAPSED/REFRACTORY B-ALL PATIENTS (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2490;
P1
For patients with low tumor burden, blinatumomab has similar therapeutic efficacy with hCART19. Thus, for patients with low tumor burden, blinatumomab is a good choice while for high tumor burden, hCART19 is a good choice.
- Blincyto (blinatumomab) / Astellas, Amgen
SAFETY AND EFFICACY COMPARISON OF HUMANIZED CD19 CAR-T VERSUS BLINATUMOMAB THERAPY FOR RELAPSED/REFRACTORY B-ALL PATIENTS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2489;
P1
For patients with low tumor burden, blinatumomab has similar therapeutic efficacy with hCART19. Thus, for patients with low tumor burden, blinatumomab is a good choice while for high tumor burden, hCART19 is a good choice.
- Nplate (romiplostim) / Amgen, Kyowa Kirin
ROMIPLOSTIM TREATMENT FOR SEVERE THROMBOCYTOPENIA AFTER MIBG THERAPY AND AUTOLOGOUS HSCT IN HIGH-RISK NEUROBLASTOMA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2471;
Lack of access or no access to irradiated single-donor platelet as the healthy ones in low and middle-income countries with limited resources is a great challenge in cancer treatment. To reduce blood product consumption and complications of severe thrombocytopenia, using Romiplostim in cases with severe and long-term thrombocytopenia after receiving MIBG therapy and HSCT is recommended but needs further studies with larger number of cases.
- plerixafor / Generic mfg.
PLERIXAFOR AS A MOBILIZING AGENT FOR SALVAGE HIGH-DOSE CHEMOTHERAPY IN RELAPSED/REFRACTORY TESTICULAR CANCER: AN EXPERIENCE OF 22 CASES (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2272;
This retrospective study represents a single-center experience and the largest data collection on the use of plerixafor as a molecule able to increase PBSC mobilization in solid tumors. These findings, consistent with the reports of previous small series in GCTs, prove the efficacy of plerixafor in these pts who failed previous mobilization therapies and support its use in clinical practice.
- plerixafor / Generic mfg.
PLERIXAFOR AS A MOBILIZING AGENT FOR SALVAGE HIGH-DOSE CHEMOTHERAPY IN RELAPSED/REFRACTORY TESTICULAR CANCER: AN EXPERIENCE OF 22 CASES (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2271;
This retrospective study represents a single-center experience and the largest data collection on the use of plerixafor as a molecule able to increase PBSC mobilization in solid tumors. These findings, consistent with the reports of previous small series in GCTs, prove the efficacy of plerixafor in these pts who failed previous mobilization therapies and support its use in clinical practice.
- Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
PEGFILGRASTIM FOR STEM CELL MOBILIZATION FOLLOWED BY FRESH STEM CELL INFUSION IN MULTIPLE MYELOMA (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2232;
Health resource utilization reduced modestly with PEG during mobilization. Transplant short term outcomes were comparable without the requirement of GCSF to hasten neutrophil engraftment, and with a reduction in the transfusion requirements needs in the PEG group.
- Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
PEGFILGRASTIM FOR STEM CELL MOBILIZATION FOLLOWED BY FRESH STEM CELL INFUSION IN MULTIPLE MYELOMA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2231;
Health resource utilization reduced modestly with PEG during mobilization. Transplant short term outcomes were comparable without the requirement of GCSF to hasten neutrophil engraftment, and with a reduction in the transfusion requirements needs in the PEG group.
- Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
PEGFILGRASTIM AFTER CONDITIONING WITH BEAM AND AUTOLOGOUS HEMATOPOIETIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN LYMPHOMA PATIENTS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2230;
In our patient cohort after PBSCT, pegfilgrastim showed comparable efficacy to filgrastim but offered better compliance due to its single dose. Notable differences emerged between high-dose (HD) and non-Hodgkin lymphoma (NHL) groups: younger age at transplantation (median 32 vs. 55 years), more Rituximab use in NHL, and varied treatment-related factors.
- Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
PAEDIVOD INSIGHTS: REVIEWING VENO-OCCLUSIVE DISEASE IN PAEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2203;
Younger age, particularly <2 years and use of busulfan play a discernible role, warranting cautious consideration in clinical decision making. While certain factors present discernible risks, the absence of statistical significance in-particular with antifungal choice signals a need for further exploration
- Blincyto (blinatumomab) / Astellas, Amgen
OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOLLOWING BLINATUMOMAB IN CHILDREN AND YOUNG ADULTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2171;
HSCT following blinatumomab in children/YA with r/r B-ALL is safe and highly effective, with remarkably low NRM (only 2 patients died for NRM) and absence of unexpected toxicities. These findings indicate that blinatumomab represents a suitable strategy to achieve long-term disease eradication and that it doesn
- Blincyto (blinatumomab) / Astellas, Amgen
OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOLLOWING BLINATUMOMAB IN CHILDREN AND YOUNG ADULTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2170;
HSCT following blinatumomab in children/YA with r/r B-ALL is safe and highly effective, with remarkably low NRM (only 2 patients died for NRM) and absence of unexpected toxicities. These findings indicate that blinatumomab represents a suitable strategy to achieve long-term disease eradication and that it doesn
- Granocyte (lenograstim) / Roche, Neupogen (filgrastim) / Kyowa Kirin, Amgen
LENOGRASTIM AND FILGRASTIM: REAL-LIFE COMPARISON IN MOBILIZATION OF ALLOGENEIC HEMATOPOIETIC STEM CELL DONORS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1915;
Day 4 CD34+ cells counts are higher during filgrastim treatment, but this difference decreases at day 5, suggesting a possible slower effect of lenograstim, or a successful modulation of the last G-CSF doses according to day 4 counts. Filgrastim should still be considered a valid alternative option to lenograstim as mobilizing agent in normal donors.
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neumax (filgrastim biosimilar) / Fresenius Kabi
IMMUNOPHENOTYPING OF PERIPHERAL BLOOD MONONUCLEAR CELLS COLLECTED BY APHERESIS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1745;
Although HSCTs have been performed as a standard of care for many disorders, little is known about the effects of mobilization and apheresis collection on the graft MNC composition, which may impact the transplant outcomes. Therefore, further studies are required to verify its effects on engraftment kinetics and its clinical implications
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis, Rituxan (rituximab) / Roche
IMMUNE THROMBOCYTOPENIA FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT : RESULTS FROM A FRENCH MULTICENTRIC RETROSPECTIVE STUDY OF 35 CASES (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1736;
This study is ongoing and still recruiting. A detailed statistical analysis with follow in order to identify possible predictive and prognostic markers of ITP after HSCT.
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis, Rituxan (rituximab) / Roche
IMMUNE THROMBOCYTOPENIA FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT : RESULTS FROM A FRENCH MULTICENTRIC RETROSPECTIVE STUDY OF 35 CASES (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1735;
This study is ongoing and still recruiting. A detailed statistical analysis with follow in order to identify possible predictive and prognostic markers of ITP after HSCT.
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
FILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION SHORTENED TIME TO NEUTROPHIL RECOVERY AND HOSPITAL STAY (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1538;
Outcomes of patients who underwent an autoSCT between January 1 and September 30 2023 for multiple myeloma (after high-dose melphalan (HDM)) and lymphoma (after (R-)BEAM or rituximab/BCNU/thiotepa) were compared to outcomes of patients who underwent an autoSCT in 2021 or 2022 with the same conditioning regiments (control group).The primary goal was to evaluate whether time from autoSCT to neutrophil recovery (neutrophils ?0.5x109/L) shortened and whether the time from autoSCT to discharge shortened. Treatment with filgrastim after autoSCT shortened time to neutrophil recovery and the hospital stay without any adverse events within the follow-up period of this study.Based on this study we suggest to administer filgrastim after autoSCT with HDM, (R-)BEAM and rituximab/BCNU/thiotepa conditioning regiments (dosage 30 million units once a day from day +5 until neutrophil recovery).
- EFFICACY OF SALVAGE THERAPY INCLUDING NOVEL AGENTS IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (B-ALL) PROGRESSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A REAL-WORLD UK STUDY (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1425;
The efficacy of 2nd allo-SCT is limited, unless utilized as post-CAR-T consolidation. DLI emerges as a potentially beneficial intervention and its impact should be explored in other datasets to confirm this finding.
- EFFICACY OF SALVAGE THERAPY INCLUDING NOVEL AGENTS IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (B-ALL) PROGRESSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A REAL-WORLD UK STUDY (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1424;
The efficacy of 2nd allo-SCT is limited, unless utilized as post-CAR-T consolidation. DLI emerges as a potentially beneficial intervention and its impact should be explored in other datasets to confirm this finding.
- Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
EARLY DETECTION OF RELAPSE AND PROMPT TREATMENT WITH DLI FACILITATED BY PROPHYLACTIC LYMPHOCYTE STORAGE PERI-TRANSPLANT RESULTS IN EFFECTIVE DISEASE CONTROL IN ACUTE LEUKAEMIA AND MDS (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1358;
High levels of durable disease control are achieved and low rates of GvHD are seen resultant on DLI dose escalation. Prophylactic storage of DLI allows this approach and is cost effective
- Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
EARLY DETECTION OF RELAPSE AND PROMPT TREATMENT WITH DLI FACILITATED BY PROPHYLACTIC LYMPHOCYTE STORAGE PERI-TRANSPLANT RESULTS IN EFFECTIVE DISEASE CONTROL IN ACUTE LEUKAEMIA AND MDS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1357;
High levels of durable disease control are achieved and low rates of GvHD are seen resultant on DLI dose escalation. Prophylactic storage of DLI allows this approach and is cost effective
- DONOR-DERIVED LYMPHOID ANTIGEN-DIRECTED CAR-T CELLS FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REPORT OF 17 CASES (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1342;
Our early experience suggests that donor-derived lymphoid antigen-directed CAR-T cells expand in vivo and may provide CR with manageable safety profile. Prospective testing and further research of the approach is warranted.
- DONOR-DERIVED LYMPHOID ANTIGEN-DIRECTED CAR-T CELLS FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REPORT OF 17 CASES (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1341;
Our early experience suggests that donor-derived lymphoid antigen-directed CAR-T cells expand in vivo and may provide CR with manageable safety profile. Prospective testing and further research of the approach is warranted.
- DONOR-DERIVED CAR-T CELLS ARE SAFELY AND EFFECTIVELY CO-INFUSED WITH THE ALLOGENIC GRAFT, DEPLETED OF AB T CELLS IN CHILDREN WITH ADVANCED B-CELL NEOPLASM (Hall 3 South) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1334;
Prospective testing and further research of the approach is warranted. All patients had relapse after multiple lines of treatment including previous HSCT(n=10), blinatumomab (n=12), inotuzumab (n=1) and CAR-T cell infusion(n=8)...PBMS used to produce CAR T cells were provided by the patient
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
CRYOPRESERVATION IS NOT STRICTLY NECESSARY TO PERFORM ASCT IN LYMPHOMA PATIENTS WITH BEAM REGIMEN. A SINGLE CENTER EXPERIENCE FROM PARAGUAY (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1250;
It is possible to perform ASCT for lymphoma patients without cryopreservation. The conditioning regimen of choice is BEAM modified, that has been used in a save manner in limited resource settings.
- CD22-TARGETED IMMUNOTHERAPY FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-ALL WHO PREVIOUSLY EXPOSED TO CD19-TARGETED IMMUNOTHERAPY (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1091;
However, the relapse rate post CD22-targeted immunotherapy remains high. Therefore, new strategies are still needed to improve the prognosis of this group of patients.
- CD22-TARGETED IMMUNOTHERAPY FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-ALL WHO PREVIOUSLY EXPOSED TO CD19-TARGETED IMMUNOTHERAPY (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1090;
However, the relapse rate post CD22-targeted immunotherapy remains high. Therefore, new strategies are still needed to improve the prognosis of this group of patients.
- Blincyto (blinatumomab) / Astellas, Amgen
BLINATUMOMAB IS AN EFFECTIVE AND LOW TOXICITY BRIDGE TREATMENT TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA ASSOCIATED WITH SHWACHMAN- DIAMOND SYNDROME (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1049;
Children with SDS develop AML in 12-25% of cases, while ALL rarely occurs. Only two cases of lymphoid malignancies in patients with SDS have been described: 1 patient in 1978 with ALL and a postmortem SDS diagnosis based on pancreatic histology and 1 patient with primary mediastinal B cell lymphoma.
- BCG-VACCINE COMPLICATIONS IN CHILDREN WITH INFANT ACUTE LYMPHOBLASTIC LEUKEMIA (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1032;
The cause may be in incomplete clearence of life Mbt.bovis due to young age, followed by intensive immunoablation. Moreover, in some patients (likely P3 and P5) BCGitis may be potentiated by hematologic/immune recovery.
- BCG-VACCINE COMPLICATIONS IN CHILDREN WITH INFANT ACUTE LYMPHOBLASTIC LEUKEMIA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1031;
The cause may be in incomplete clearence of life Mbt.bovis due to young age, followed by intensive immunoablation. Moreover, in some patients (likely P3 and P5) BCGitis may be potentiated by hematologic/immune recovery.
- thiotepa / Generic mfg.
AUTOLOGOUS HEMATOPIETIC STEM CELL TRANSPLANT IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA WITH BUSULPHAN THIOTEPA CONDITIONING (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_999;
A single centre study by Schorb et al [MARiTA study] explored Busulphan-Thiotepa conditioning protocol.It was well tolerated with zerotransplant related mortality, two year overall survival of 92% and two year progression free survival [PFS] of 89%. A select group of elderly patients with PCNSL can be offered autologous HSCT as a consolidation strategy
- Jakafi (ruxolitinib) / Novartis, Incyte, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
ALLOGENEIC STEM CELL TRANSPLANTATION IN THE MANAGEMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA: A TEN YEAR EXPERIENCE IN IRELAND (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_924;
Of those with acute-GVHD, 15 cases (24%) were steroid refractory requiring additional therapies including ruxolitinib, mycophenolate-mofetil, extracorporeal-photopheresis and ATG.30 patients (34%) developed viral reactivation involving CMV, EBV or adenovirus...Treatment strategies at relapse included blinatumomab, inotuzumab, Hyper-CVAD, nelarabine, TKIs, palliation and CAR-T therapy.27 patients (30%) died during follow-up at a median time of 9 months (1-71) post-transplant; relapse-related mortality N=11 (12%), transplant-related mortality (TRM) N=14 (16%), lost to follow-up N=2 (2%)... AlloSCT in high-risk patients is an effective strategy for the management of adult ALL with a 5 year OS of 69% in this cohort.
- Blincyto (blinatumomab) / Astellas, Amgen
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA. A SURVEY BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_900;
TBI-based conditioning appears preferable in this patient population. Our data can serve as reference for results of prospective trials
- Blincyto (blinatumomab) / Astellas, Amgen
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA. A SURVEY BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_899;
TBI-based conditioning appears preferable in this patient population. Our data can serve as reference for results of prospective trials
- Blincyto (blinatumomab) / Astellas, Amgen
20-YEAR STEADY INCREASE IN POST-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES FOR PATIENTS WITH PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA. A STUDY FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY (Hall 5) - Feb 14, 2024 - Abstract #EBMT2024EBMT_791;
In patients with Ph+ ALL, we observed an impressive improvement over time in post-transplant outcomes with decreased CIR and NRM and improved LFS, OS, and GRFS, both in MRDpos and MRDneg patients. These large-scale, real-world data can serve as a benchmark for future studies in this setting, including those testing the combination of TKI and blinatumomab as an alternative to transplant.
- || Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier, Simdax (levosimendan IV) / AbbVie
Review, Journal: Current Approaches to Worsening Heart Failure: Pathophysiological and Molecular Insights. (Pubmed Central) - Feb 14, 2024
Regarding device-based therapies, invasive pulmonary pressure measurement and cardiac contractility modulation have emerged as promising tools to increase the quality of life and reduce hospitalizations due to HF exacerbations. Recent innovations in terms of WHF management emphasize the need for a multifaceted and patient-centric approach to address the complex HF syndrome.
- | Ibrance (palbociclib) / Pfizer
Journal: Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy. (Pubmed Central) - Feb 14, 2024
The literature data and bioinformatic tools provide an underlying molecular rationale for most of these miRNAs, mainly involving the PI3K/AKT/mTOR pathway and cell-cycle machinery as cyclin D1, CDKN1B, and protein p27Kip1 and autophagy. Our findings propose a novel panel of miRNAs associated with a higher likelihood of early progression in patients treated with ET and Palbociclib and may contribute to shed some light on the mechanisms of de novo resistance to CDK4/6i, but this should be considered exploratory and evaluated in larger cohorts.
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: EPI-SURVEY. Grade of awareness of Spanish allergist, hospital pharmacist, and pulmonologists on the relevance of bronchial epithelium and alarmins in the pathogenesis and management of severe asthma. (Pubmed Central) - Feb 14, 2024
Our findings propose a novel panel of miRNAs associated with a higher likelihood of early progression in patients treated with ET and Palbociclib and may contribute to shed some light on the mechanisms of de novo resistance to CDK4/6i, but this should be considered exploratory and evaluated in larger cohorts. No abstract available
- ||| TTI-101 oral / Tvardi Therap
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: REVERT: Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer (clinicaltrials.gov) - Feb 14, 2024
P1/2, N=6, Active, not recruiting, Sponsor: Tvardi Therapeutics, Incorporated
No abstract available Recruiting --> Active, not recruiting | N=53 --> 6 | Trial completion date: Feb 2025 --> Jun 2024 | Trial primary completion date: Dec 2024 --> Jun 2024
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Denosumab and the Risk of Diabetes in Patients Treated for Osteoporosis. (Pubmed Central) - Feb 13, 2024
Several sensitivity analyses also demonstrated similar results of lower diabetes risk associated with denosumab treatment. The results from this cohort study indicating that denosumab treatment was associated with lower risk of incident diabetes may help physicians choose an appropriate antiosteoporosis medication for patients with osteoporosis while also considering the risk of diabetes.
- | Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Journal: Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer. (Pubmed Central) - Feb 13, 2024
The results from this cohort study indicating that denosumab treatment was associated with lower risk of incident diabetes may help physicians choose an appropriate antiosteoporosis medication for patients with osteoporosis while also considering the risk of diabetes. Administration of pegfilgrastim on day 3 was not sufficient to prevent FN due to DCF treatment, and prophylactic administration of both pegfilgrastim and antibiotics could be a solution.
- || Enbrel (etanercept) / Pfizer, Amgen
Clinical, Review: Etanercept treatment for pediatric toxic epidermal necrolysis induced by deflazacort: a case report and literature review. (Pubmed Central) - Feb 13, 2024
No acute or sub-acute complications were observed. In conclusion, the use of etanercept in children with TEN that is not controlled with conventional therapy is both effective and safe.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Effect of anti-CGRP-targeted therapy on migraine aura: Results of an observational case series study. (Pubmed Central) - Feb 13, 2024
Conversely, these antibodies are able to counteract, via their peripheral mechanisms of action, the sensitization of the trigemino-vascular pathway which is triggered by CSD. This aforementioned might explain why in our patients, migraine aura attacks remained unchanged in their frequencies, but the headache phases were either reduced or absent.
- | Lumakras (sotorasib) / Amgen
Biomarker, Journal: Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. (Pubmed Central) - Feb 13, 2024
This aforementioned might explain why in our patients, migraine aura attacks remained unchanged in their frequencies, but the headache phases were either reduced or absent. Sotorasib showed selective inhibition in
- Prolia (denosumab) / Amgen
OSTEOLYSIS OF THE PARIETAL BONE IN A PATIENT WITH SYSTEMIC SCLEROSIS MIMICKING GORHAM-STOUT DISEASE (Poster Area) - Feb 13, 2024 - Abstract #SSWC2024SSWC_192;
There were no neurological symptoms other than parietal area pain. The patient will be monitored with computed tomography for the progression of bone resorption.
- | Parsabiv (etelcalcetide) / Amgen
Journal, HEOR: An Initial Low-Dose Etelcalcetide Dosing Strategy in Hemodialysis Patients With Moderate Secondary Hyperparathyroidism is Effective and Cost-Saving. (Pubmed Central) - Feb 12, 2024
The patient will be monitored with computed tomography for the progression of bone resorption. No abstract available
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal, Real-world evidence, Real-world, Metastases: Role of Cyclin-Dependent Kinase 4/6 in Metastatic Breast Cancer: Real-World Data From a Tertiary Care Institute in Eastern India. (Pubmed Central) - Feb 12, 2024
Both drugs have well-tolerated toxicity, allowing patients to continue taking them for an extended period of time. CDK4/6 inhibitors have a higher response rate than the other agents.
- | Ibrance (palbociclib) / Pfizer
Journal: miR-6883 downregulates HIF1? in colorectal and breast cancer cells. (Pubmed Central) - Feb 12, 2024
in CRC and BC cells, pointing to miR-6883 as a promising therapeutic to target hypoxic tumors or HIF1?-deregulated cancer cells. Future studies will further investigate miR-6883 as a cancer biomarker, effects on HIF-related proteins, and therapeutic uses in vivo .
- | latikafusp (AMG 256) / Amgen
Preclinical, Journal: Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1/IL-21 mutein fusion protein. (Pubmed Central) - Feb 12, 2024
ADA responses were not associated with any type of adverse event. The AMG 256 program represents a unique case where nonclinical studies informed on the risk of immunogenicity in humans, due to the IL-21-driven nature of the response.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Efficacy and risk of osteonecrosis of the jaw for pamidronate, zoledronic acid, and denosumab in comparison to alendronate in multiple myeloma patients. (Pubmed Central) - Feb 12, 2024
This study shows that fracture reduction risk is comparable for all four treatments in multiple myeloma patients, but ONJ risk is lowest for alendronate and pamidronate. Overall, these data support the continued use of pamidronate and alendronate in multiple myeloma patients.
- | Repatha (evolocumab) / Amgen, Astellas
Retrospective data, Journal: A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels. (Pubmed Central) - Feb 12, 2024
The evolocumab LDL-C-lowering effect observed in clinical trials was confirmed in clinical practice in Sweden, particularly in patients also treated with oral LLT. During follow-up, adherence to and persistence with evolocumab were high, with stable reduced levels of LDL-C during observation.